rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2020-106-111rsp-2851Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSЭффективность анти-В-клеточной терапии у больных с нейропсихическими проявлениями системной красной волчанки (описание клинических случаев)Efficiency of anti-B-cell therapy in patients with neuropsychiatric manifestations of systemic lupus erythematosus: a report of clinical casesКойлубаеваГ. М.KoilubaevaG. M.

Гулазик Маликовна Койлубаева

720040, Кыргызстан, Бишкек, ул. Тоголока Молдо, 3

Gulazik Koilubaeva

3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan

makmal@rambler.ruАсееваЕ. А.AseevaE. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

СоловьевС. К.SolovyevS. K.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

НикишинаН. Ю.NikishinaN. Yu.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34А; 119991, Москва, ул. Трубецкая, 8, стр. 2

34A, Kashirskoe Shosse, Moscow 115522; 8, Trubetskaya St., Build. 2, Moscow 119991

ДжумагуловаА. С.DzhumagulovaА. S.

720040, Кыргызстан, Бишкек, ул. Тоголока Молдо, 3

3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan

ТкаченкоН. П.TkachenkoN. P.

720040, Кыргызстан, Бишкек, ул. Тоголока Молдо, 3

3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan

КаримоваЭ. Р.KarimovaЕ. R.

720040, Кыргызстан, Бишкек, ул. Тоголока Молдо, 3

3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan

МолдобаеваА. А.MoldobaevaA. A.

720040, Кыргызстан, Бишкек, ул. Тоголока Молдо, 3

3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan

ЖумакадыроваА. Ж.ZhumakadyrovaA. Zh.

720040, Кыргызстан, Бишкек, ул. Тоголока Молдо, 3

3, Togolok Moldo St., Bishkek 720040, Kyrgyzstan

Национальный Центр кардиологии и терапии (НЦКТ) им. академика М. МиррахимоваКыргызстанAcademician M. Mirrakhimov National Center for Cardiology and TherapyKyrgyzstanФГБНУ «Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation202020022020581106111Copyright © Койлубаева Г.М., Асеева Е.А., Соловьев С.К., Никишина Н.Ю., Насонов Е.Л., Джумагулова А.С., Ткаченко Н.П., Каримова Э.Р., Молдобаева А.А., Жумакадырова А.Ж., 20202020Койлубаева Г.М., Асеева Е.А., Соловьев С.К., Никишина Н.Ю., Насонов Е.Л., Джумагулова А.С., Ткаченко Н.П., Каримова Э.Р., Молдобаева А.А., Жумакадырова А.Ж.Koilubaeva G.M., Aseeva E.A., Solovyev S.K., Nikishina N.Y., Nasonov E.L., Dzhumagulova А.S., Tkachenko N.P., Karimova Е.R., Moldobaeva A.A., Zhumakadyrova A.Z.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2851

Представлены два клинических наблюдения у больных системной красной волчанкой (СКВ) с тяжелым поражением нервной системы, характеризовавшимся в одном случае диффузными и очаговыми нейропсихическими проявлениями СКВ со стороны центральной нервной системы и поражением периферической нервной системы в виде локального мононеврита нижних конечностей, в другом случае — тяжелой периферической невропатией, проявившейся множественным мононевритом нижних конечностей. Отмечается эффект анти-В-клеточной терапии ритуксимабом.

The paper describes two patients with systemic lupus erythematosus (SLE) with severe nervous system damage characterized by diffuse and focal neuropsychiatric manifestations of SLE due to of the central nervous system involvement and damage to the peripheral nervous system as local mononeuritis of the lower extremities in one case and severe peripheral neuropathy manifested by multiple mononeuritis of the lower extremities in the other. Anti-B cell therapy with rituximab is noted to have an effect.

системная красная волчанканейропсихические проявленияцентральная нервная системапериферическая нервная системаанти-В-клеточная терапияритуксимабsystemic lupus erythematosusneuropsychiatric manifestationscentral nervous systemperipheral nervous systemanti-B-cell therapyrituximabНастоящее исследование выполнено в рамках фунамен-тальной научной темы N AAA-A19-119021190145-2 по фрагменту «РЕНЕССАНС»ReferencesНасонов ЕЛ. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. C. 42981Nasonov EL. Klinicheskie rekomendatsiipo revmatologii [Clinical guidelines for rheumatology]. 2nd ed. Moscow: GEOTAR-Media; 2010. P. 429-81 (In Russ.).The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599-608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-FThe American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599-608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-FPiga M, Mathieu A. Managing CNS involvement in systemic lupus erythematosus. Int JClin Rheumatol. 2011;6:547-67. doi: 10.2217/ijr.11.44Piga M, Mathieu A. Managing CNS involvement in systemic lupus erythematosus. Int JClin Rheumatol. 2011;6:547-67. doi: 10.2217/ijr.11.44Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-8. doi: 10.1093/rheumatology/keu384Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-8. doi: 10.1093/rheumatology/keu384Piga M, Casula L, Perra D, et al. Population-based analysis of hospital-izations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus. 2016;25:28-37. doi: 10.1177/0961203315596597Piga M, Casula L, Perra D, et al. Population-based analysis of hospital-izations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012. Lupus. 2016;25:28-37. doi: 10.1177/0961203315596597Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neu-ropsychiat-ric events in systemic lupus erythematosus upon enrollment into an inter-national inception cohort study. Arthritis Rheum. 2008;59(5):721-9. doi: 10.1002/art.23566Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neu-ropsychiat-ric events in systemic lupus erythematosus upon enrollment into an inter-national inception cohort study. Arthritis Rheum. 2008;59(5):721-9. doi: 10.1002/art.23566Zirkzee EJ, Huizinga TW, Bollen EL, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23:31-8. doi: 10.1177/0961203313512540Zirkzee EJ, Huizinga TW, Bollen EL, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23:31-8. doi: 10.1177/0961203313512540Piga M, Chessa E, Peltz MT, et al. Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017;16(3):244-52. doi: 10.1016/j.autrev.2017.01.011Piga M, Chessa E, Peltz MT, et al. Demyelinating syndrome in SLE encompasses different subtypes: do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev. 2017;16(3):244-52. doi: 10.1016/j.autrev.2017.01.011Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi: 10.1002/art.22305Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265-73. doi: 10.1002/art.22305Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommen-da-tions for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-82. doi: 10.1136/ard.2010.130476Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommen-da-tions for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074-82. doi: 10.1136/ard.2010.130476Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroidsparing regimen. Rheumatology (Oxford). 2012;51(3):476-81. doi: 10.1093/rheumatology/ker337Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroidsparing regimen. Rheumatology (Oxford). 2012;51(3):476-81. doi: 10.1093/rheumatology/ker337Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treat-ment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717-23. doi: 10.1093/ndt/gfp336Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treat-ment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717-23. doi: 10.1093/ndt/gfp336Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi: 10.1002/art.34473Petri M, Orbai A, Alarson G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi: 10.1002/art.34473Shessa E, Piga M, et al. Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab an alternative to standard of care. Open Access Rheumatology: Research and Reviews, 11 September, 2017. P. 167-8. doi: 10.2147/OARRR.S143768Shessa E, Piga M, et al. Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab an alternative to standard of care. Open Access Rheumatology: Research and Reviews, 11 September, 2017. P. 167-8. doi: 10.2147/OARRR.S143768Steri M, Orru V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376(17):1615-26. doi: 10.1056/NEJMoa1610528Steri M, Orru V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017;376(17):1615-26. doi: 10.1056/NEJMoa1610528Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894):819-31. doi: 10.1016/S0140-6736(13)60954-XWahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894):819-31. doi: 10.1016/S0140-6736(13)60954-XFloris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev. 2016;15(7):656-63. doi: 10.1016/j.autrev.2016.02.019Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev. 2016;15(7):656-63. doi: 10.1016/j.autrev.2016.02.019Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587):1689-92. doi: 10.1126/science.1073176Lee DM, Friend DS, Gurish MF, et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002;297(5587):1689-92. doi: 10.1126/science.1073176Lovgren T, Eloranta ML, Bave U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861-72. doi: 10.1002/art.20254Lovgren T, Eloranta ML, Bave U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861-72. doi: 10.1002/art.20254Martin F, Chan AC. B-cell immunobiology in disease: evolving concepts from the clinic. Ann Rev Immunol. 2006;24:467-96. doi: 10.1146/annurev.immunol.24.021605.090517Martin F, Chan AC. B-cell immunobiology in disease: evolving concepts from the clinic. Ann Rev Immunol. 2006;24:467-96. doi: 10.1146/annurev.immunol.24.021605.090517Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immu-nostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol. 1999;163(11):6306-13.Vallin H, Perers A, Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immu-nostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol. 1999;163(11):6306-13.Piga M, Gabba A, Cauli A, et al. Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultraso-nographic monitoring of response. A longitudinal pilot study. Lupus. 2013;22 (6):624-8. doi: 10.1177/0961203313482741Piga M, Gabba A, Cauli A, et al. Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultraso-nographic monitoring of response. A longitudinal pilot study. Lupus. 2013;22 (6):624-8. doi: 10.1177/0961203313482741Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364-72. doi: 10.1016/j.semarthrit.2011.06.004Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364-72. doi: 10.1016/j.semarthrit.2011.06.004Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66 (4):470-5. doi: 10.1136/ard.2006.057885Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66 (4):470-5. doi: 10.1136/ard.2006.057885Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-47. doi: 10.1038/nrrheum.2014.15Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338-47. doi: 10.1038/nrrheum.2014.15Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41-72. doi: 10.1016/j.jaut.2016.06.013Govoni M, Bortoluzzi A, Padovan M, et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun. 2016;74:41-72. doi: 10.1016/j.jaut.2016.06.013Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484. doi: 10.3389/fimmu.2013.00484Stock AD, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol. 2013;4:484. doi: 10.3389/fimmu.2013.00484Fanouriakis A, Pamfil C, Rednic S, et al. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol. 2016;34(5):910-7. Epub 2016 Jul 26.Fanouriakis A, Pamfil C, Rednic S, et al. Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clin Exp Rheumatol. 2016;34(5):910-7. Epub 2016 Jul 26.Ho RC, Thiaghu C, Ong H. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016;15:124-38. doi: 10.1016/j.autrev.2015.10.003Ho RC, Thiaghu C, Ong H. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016;15:124-38. doi: 10.1016/j.autrev.2015.10.003Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43. doi: 10.1186/s12916-015-0269-8. PMid:25858312Kivity S, Agmon-Levin N, Zandman-Goddard G, et al. Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med. 2015;13:43. doi: 10.1186/s12916-015-0269-8. PMid:25858312Gladman DD, Urowitz B, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955-9.Gladman DD, Urowitz B, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(9):1955-9.Piga M, Peltz MT, Montaldo C, et al. Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev. 2015;14(6):510-6. doi: 10.1016/j.autrev.2015.01.010Piga M, Peltz MT, Montaldo C, et al. Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev. 2015;14(6):510-6. doi: 10.1016/j.autrev.2015.01.010Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidi-ties associated with first central nervous system neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicenter retrospective cross sectional study on 959 Italian patients. Rheumatology (Oxford). 2012;51:157-68. doi: 10.1093/rheumatology/ker310Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidi-ties associated with first central nervous system neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicenter retrospective cross sectional study on 959 Italian patients. Rheumatology (Oxford). 2012;51:157-68. doi: 10.1093/rheumatology/ker310

The authors declare that there are no conflicts of interest present.